Search - tctmd.com

Displaying 201 - 220 of 671

Sort: Relevancy | Date

Presentation SOLACI 2016

The Unmet Needs of DES

Presenter: Roxana Mehran

June 09, 2016

Presentation SOLACI 2016

Drug-eluting Stent and Dual Platelet Aggregation: What We Must Know

Presenter: Eduardo Nagib

June 09, 2016

Presentation SOLACI 2016

Adjunctive Pharmacology for Patients with ACS Treated Invasively

Presenter: Eric R. Bates

June 09, 2016

Presentation SOLACI 2016

Mitos e verdades sobre o uso de antiplaquetários na intervenção percutânea

Presenter: Roberto Esporcatte

June 08, 2016

Presentation SOLACI 2016

LATIN Project: Primary PCI and telemedicine

Presenter: Marco Perin

June 08, 2016

Presentation EuroPCR 2016

Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a LEADERS FREE ACS substudy

Presenter: Christoph Naber

May 19, 2016

Presentation EuroPCR 2016

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Presenter: Robert-Jan van Geuns

May 18, 2016

Presentation

Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses

Presenter: Haris Riaz

May 11, 2016

Presentation

Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Following PCI

Presenter: Amit N. Vora

April 22, 2016

Presentation Fellows 2016

Case 2

Presenter: Ajay Kirtane

April 15, 2016

Presentation Fellows 2016

Case 1: Dilemmas in DAPT and PCI Pharmacology

Presenter: Allen Jeremias

April 15, 2016

Presentation Fellows 2016

Antiplatelet Therapy for the Interventionalist

Presenter: Roxana Mehran

April 15, 2016

Presentation

CRUSH: Crushed Prasugrel Tablets in STEMI Patients Undergoing Primary PCI

Presenter: Fabiana Rollini

March 28, 2016

Presentation

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Presenter: Muthia Vaduganathan

March 22, 2016

Presentation

Is BMS Implantation Still Justifiable in High Bleeding Risk Patients Undergoing PCI?

Presenter: Sara Ariotti

March 07, 2016

Presentation

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

Presenter: Grant Reed

February 28, 2016

Presentation

Stopping vs Continuing Aspirin Before Coronary Artery Surgery

Presenter: Paul Myles

February 24, 2016

Presentation JIM 2016

Optimal Duration of Oral Antiplatelet Therapy

Presenter: Dominick J. Angiolillo

February 11, 2016

Presentation JIM 2016

Medical therapy optimization with new anti-ischemic drugs

Presenter: Giuseppe Musumeci

February 11, 2016

Presentation JIM 2016

GP2b3a blockers:Back to the future

Presenter: Arnoud van ?t Hof

February 11, 2016

Advertisement

The Unmet Needs of DES

Drug-eluting Stent and Dual Platelet Aggregation: What We Must Know

Adjunctive Pharmacology for Patients with ACS Treated Invasively

Mitos e verdades sobre o uso de antiplaquetários na intervenção percutânea

LATIN Project: Primary PCI and telemedicine

Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a LEADERS FREE ACS substudy

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses

Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Following PCI

Case 2

Case 1: Dilemmas in DAPT and PCI Pharmacology

Antiplatelet Therapy for the Interventionalist

CRUSH: Crushed Prasugrel Tablets in STEMI Patients Undergoing Primary PCI

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Is BMS Implantation Still Justifiable in High Bleeding Risk Patients Undergoing PCI?

Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs by Dose: GRAVITAS

Stopping vs Continuing Aspirin Before Coronary Artery Surgery

Optimal Duration of Oral Antiplatelet Therapy

Medical therapy optimization with new anti-ischemic drugs

GP2b3a blockers:Back to the future

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content